Heruntergeladen Urheberrechtlich

194
Leitlinie
185 Ewig S, Torres A, Angeles Marcos M et al. Factors associated with unknown
aetiology in patients with community-acquired pneumonia.
Eur Respir J 2002; 20: 1254 – 1262
186 Halm EA, Fine MJ, Marrie TJ et al. Time to clinical stability in patients
hospitalized with community-acquired pneumonia: implications for
practice guidelines. JAMA 1998; 279: 1452 – 1457
187 Fine MJ, Smith DN, Singer DE. Hospitalization decision in patients with
community-acquired pneumonia: a prospective cohort study. Am J
Med 1990; 89: 713 – 721
188 Halm EA, Fine MJ, Kapoor WN et al. Instability on hospital discharge
and the risk of adverse outcomes in patients with pneumonia. Arch
Intern Med 2002; 162: 1278 – 1284
189 Ruiz-González A, Falguera M, Porcel JM et al. C-reactive protein for
discriminating treatment failure from slow responding pneumonia.
Eur J Intern Med 2010; 21: 548 – 552
190 Coelho L, Póvoa P, Almeida E et al. Usefulness of C-reactive protein in
monitoring the severe community-acquired pneumonia clinical
course. Crit Care 2007; 11: R92
191 Coelho LM, Salluh JI, Soares M et al. Patterns of c-reactive protein
RATIO response in severe community-acquired pneumonia: a cohort
study. Crit Care 2012; 16: R53
192 Little BP, Gilman MD, Humphrey KL et al. Outcome of recommendations
for radiographic follow-up of pneumonia on outpatient chest
radiography. AJR Am J Roentgenol 2014; 202: 54 – 59
193 Mortensen EM, Copeland LA, Pugh MJ et al. Diagnosis of pulmonary
malignancy after hospitalization for pneumonia. Am J Med 2010;
123: 66 – 71
194 Syrjälä H, Broas M, Suramo I et al. High-resolution computed tomography
for the diagnosis of community-acquired pneumonia. Clin Infect
Dis 1998; 27: 358 – 363
195 von Baum H, Ewig S, Marre R et al. Community-acquired Legionella
pneumonia: new insights from the German competence network for
community acquired pneumonia. Clin Infect Dis 2008; 46: 1356 –
1364
196 Wellinghausen N, Straube E, Freidank H et al. Low prevalence of Chlamydia
pneumoniae in adults with community-acquired pneumonia.
Int J Med Microbiol 2006; 296: 485 – 491
197 Dumke R, Schnee C, Pletz MW et al. Mycoplasma pneumoniae and
Chlamydia spp. infection in community-acquired pneumonia, Germany,
2011-2012. Emerg Infect Dis 2015; 21: 426 – 434
198 von Baum H, Welte T, Marre R et al. Mycoplasma pneumoniae pneumonia
revisited within the German Competence Network for Community-acquired
pneumonia (CAPNETZ). BMC Infect Dis 2009; 9: 62
199 Imöhl M, van der Linden M. [Invasive pneumococcal disease in Germany
in the era of pneumococcal conjugate vaccination]. Dtsch Med
Wochenschr 2015; 139: 1346 – 1351
200 Pletz MW, McGee L, Burkhardt O et al. Ciprofloxacin treatment failure
in a patient with resistant Streptococcus pneumoniae infection following
prior ciprofloxacin therapy. Eur J Clin Microbiol Infect Dis
2005; 24: 58 – 60
201 Ben-Ami R, Rodríguez-Baño J, Arslan H et al. A multinational survey of
risk factors for infection with extended-spectrum beta-lactamaseproducing
enterobacteriaceae in nonhospitalized patients. Clin Infect
Dis 2009; 49: 682 – 690
202 Creutz P, Kothe H, Braun M et al. Failure of Ambulatory Treatment in
CAP Patients Leading to Subsequent Hospitalization and its Association
to Risk Factors - Prospective Cohort Study. J Pulmon Resp Med
2013; 3: 1 – 7
203 Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired
pneumonia among adults in Europe. Thorax 2012;
67: 71 – 79
204 Lode H. Role of sultamicillin and ampicillin/sulbactam in the treatment
of upper and lower bacterial respiratory tract infections. Int J
Antimicrob Agents 2001; 18: 199 – 209
205 Nie W, Li B, Xiu Q. β-Lactam/macrolide dual therapy versus β-lactam
monotherapy for the treatment of community-acquired pneumonia
in adults: a systematic review and meta-analysis. J Antimicrob Chemother
2014; 69: 1441 – 1446
206 Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics
compared with antibiotics active against atypical pathogens in nonsevere
community acquired pneumonia: meta-analysis. BMJ 2005;
330: 456
207 Tessmer A, Welte T, Martus P et al. Impact of intravenous {beta}-
lactam/macrolide versus {beta}-lactam monotherapy on mortality
in hospitalized patients with community-acquired pneumonia. J
Antimicrob Chemother 2009; 63: 1025 – 1033
208 Garin N, Genné D, Carballo S et al. β-Lactam monotherapy vs β-
lactam-macrolide combination treatment in moderately severe community-acquired
pneumonia: a randomized noninferiority trial.
JAMA Intern Med 2014; 174: 1894 – 1901
209 Postma DF, van Werkhoven CH, van Elden LJ et al. Antibiotic treatment
strategies for community-acquired pneumonia in adults. N Engl J
Med 2015; 372: 1312 – 1323
210 Guo D, Cai Y, Chai D et al. The cardiotoxicity of macrolides: a systematic
review. Pharmazie 2010; 65: 631 – 640
211 von Baum H, Schweiger B, Welte T et al. How deadly is seasonal influenza-associated
pneumonia? The German Competence Network for
Community-Acquired Pneumonia. Eur Respir J 2011; 37: 1151 – 1157
212 Louie JK, Yang S, Acosta M et al. Treatment with neuraminidase inhibitors
for critically ill patients with influenza A (H1N1)pdm09.
Clin Infect Dis 2012; 55: 1198 – 1204
213 Rodríguez A, Díaz E, Martín-Loeches I et al. Impact of early oseltamivir
treatment on outcome in critically ill patients with 2009 pandemic
influenza A. J Antimicrob Chemother 2011; 66: 1140 – 1149
214 Jefferson T, Jones MA, Doshi P et al. Neuraminidase inhibitors for preventing
and treating influenza in healthy adults and children. Cochrane
Database Syst Rev 2012; 1: CD008965
215 Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase
inhibitors in reducing mortality in patients admitted to hospital
with influenza A H1N1pdm09 virus infection: a meta-analysis of individual
participant data. Lancet Respir Med 2014; 2: 395 – 404
216 Viasus D, Paño-Pardo JR, Pachón J et al. Factors associated with severe
disease in hospitalized adults with pandemic (H1N1) 2009 in Spain.
Clin Microbiol Infect 2011; 17: 738 – 746
217 Klapdor B, Ewig S, Schaberg T et al. Presentation, etiology and outcome
of pneumonia in younger nursing home residents. J Infect
2012; 65: 32 – 38
218 Kett DH, Cano E, Quartin AA et al. Implementation of guidelines for
management of possible multidrug-resistant pneumonia in intensive
care: an observational, multicentre cohort study. Lancet Infect Dis
2011; 11: 181 – 189
219 Attridge RT, Frei CR, Restrepo MI et al. Guideline-concordant therapy
and outcomes in healthcare-associated pneumonia. Eur Respir J
2011; 38: 878 – 887
220 Madaras-Kelly KJ, Remington RE, Sloan KL et al. Guideline-based antibiotics
and mortality in healthcare-associated pneumonia. J Gen Intern
Med 2012; 27: 845 – 852
221 Biehl LM, Schmidt-Hieber M, Liss B et al. Colonization and infection
with extended spectrum beta-lactamase producing Enterobacteriaceae
in high-risk patients - Review of the literature from a clinical perspective.
Crit Rev Microbiol 2014 [Epub ahead of print: 2014 Feb 4]
222 Rodríguez-Baño J, Navarro MD, Retamar P et al. β-Lactam/β-lactam
inhibitor combinations for the treatment of bacteremia due to extended-spectrum
β-lactamase-producing Escherichia coli: a post
hoc analysis of prospective cohorts. Clin Infect Dis 2015; 54: 167 –
174
223 Garnacho-Montero J, Sa-Borges M, Sole-Violan J et al. Optimal management
therapy for Pseudomonas aeruginosa ventilator-associated
pneumonia: an observational, multicenter study comparing monotherapy
with combination antibiotic therapy. Crit Care Med 2007;
35: 1888 – 1895
224 Chamot E, Boffi E, Rohner P et al. Effectiveness of combination antimicrobial
therapy for Pseudomonas aeruginosa bacteremia. Antimicrob
Agents Chemother 2003; 47: 2756 – 2764
225 Dalhoff K, Abele-Horn M, Andreas S et al. Epidemiology, diagnosis and
treatment of adult patients with nosocomial pneumonia. S-3 Guideline
of the German Society for Anaesthesiology and Intensive Care
Medicine, the German Society for Infectious Diseases, the German
Society for Hygiene and Microbiology, the German Respiratory Society
and the Paul-Ehrlich-Society for Chemotherapy. Pneumologie
2012; 66: 707 – 765
226 Maschmeyer G, Carratalà J, Buchheidt D et al. Diagnosis and antimicrobial
therapy of lung infiltrates in febrile neutropenic patients
(allogeneic SCT excluded): updated guidelines of the Infectious Diseases
Working Party (AGIHO) of the German Society of Hematology
and Medical Oncology (DGHO). Ann Oncol 2015; 26: 21 – 33
227 Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A et al.
De-escalation of empirical therapy is associated with lower mortality
Heruntergeladen von: Deutsche Gesellschaft für Pneumologie. Urheberrechtlich geschützt.
Ewig S et al. Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention – Update 2016 … Pneumologie 2016; 70: 151–200